This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Icagen, MannKind: After-Hours Trading

NEW YORK ( TheStreet) -- Shares of Icagen (ICGN) soared on very light volume late Friday after Pfizer (PFE - Get Report) said it's considering a strategic transaction with the company, possibly a merger.

Pfizer owns roughly 1.1 million Icagen common shares, a 14.2% stake in the company, stemming from a research and licensing agreement that the Dow component entered with Icagen back in 2007.

In a Securities and Exchange Commission filing after Friday's closing bell, Pfizer detailed the stake and said it's now "evaluating the possibility of entering into a strategic transaction" with Icagen, and disclosed that representatives of both parties have held preliminary talks about a potential deal and amended prior agreements to allow Pfizer to conduct some due diligence.



Icagen, based in Research Triangle Park, N.C., issued its own statement after the close, acknowledging it's "currently engaged in preliminary discussions with Pfizer" and adding that "no definitive agreement has been reached."

Icagen shares were last quoted at $5, up more than 100%, on volume of roughly 15,000, according to Nasdaq.com. Based on a regular session close at $2.40, the stock was already up more than 35% so far in 2011.

Other stocks active in Friday's after-hours action included MannKind (MNKD), which rose nearly 8% to $4.30 on volume of 350,000. The company said after the closing bell that two separate studies of its proposed diabetes treatment Afrezza found the drug showed no increased risk of cardiac events.

MannKind also said a separate study found type 1 diabetes using Afrezza, an insulin inhalation powder, have a "more positive view of therapy" compared to compared to standard insulin therapy. MannKind shares are down almost 40% in the past 52 weeks.

Universal Forest Products (UFPI - Get Report) was also active, falling more than 15% to $22.25 on volume of more than 25,000 after the Grand Rapids, Mich.-based company said it's reducing its workforce and taking other cost-cutting actions because of weak sales.

"Retail sales during what is historically our busiest selling season didn't materialize as expected this year, and in order to preserve our opportunity for profitability and to ensure we're properly sized for our business opportunities moving forward, we have undertaken additional cost-cutting measures," said CEO Michael Glenn, in a statement.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
MNKD $4.24 -3.00%
PFE $33.67 -1.90%
UFPI $54.44 -0.48%
AAPL $126.11 -2.00%
FB $78.18 -0.80%

Markets

DOW 17,968.97 +40.77 0.23%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs